Renaissance Technologies LLC Has $4.59 Million Stake in Kodiak Sciences Inc. (NASDAQ:KOD)

Renaissance Technologies LLC reduced its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 24.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 461,600 shares of the company’s stock after selling 146,150 shares during the period. Renaissance Technologies LLC owned 0.88% of Kodiak Sciences worth $4,593,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Barclays PLC boosted its position in shares of Kodiak Sciences by 65.5% during the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after purchasing an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Kodiak Sciences by 220.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares during the period. State Street Corp increased its stake in shares of Kodiak Sciences by 1.8% in the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after acquiring an additional 14,711 shares in the last quarter. Peapod Lane Capital LLC bought a new position in Kodiak Sciences during the fourth quarter worth $1,660,000. Finally, Geode Capital Management LLC grew its holdings in Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock worth $2,007,000 after purchasing an additional 12,783 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Trading Up 14.4 %

NASDAQ KOD opened at $3.25 on Tuesday. The company has a fifty day simple moving average of $3.37 and a 200 day simple moving average of $5.40. Kodiak Sciences Inc. has a 12-month low of $1.92 and a 12-month high of $11.60. The company has a market cap of $171.43 million, a P/E ratio of -0.89 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.06. Sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating and set a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.